highperformr logo

Biogen's Overview

Total employees7675
HeadquartersCambridge
Founded

Biogen is a global biotechnology company pioneering in neuroscience. Founded in 1978, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. The company has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is at the forefront of research for Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

Where is Biogen's Headquarters?

HQ Function

Serves as the central hub for global operations, research and development leadership, corporate strategy, and administrative functions.

Notable Features:

State-of-the-art research laboratories and office spaces integrated within Kendall Square, known for its high concentration of biotech and pharmaceutical companies and academic institutions like MIT.

Work Culture:

Characterized by a strong emphasis on scientific innovation, collaboration, patient-focus, and a fast-paced environment driven by the pursuit of breakthrough therapies.

HQ Significance:

The Cambridge headquarters is pivotal for Biogen's R&D strategy, fostering collaborations and attracting top scientific talent. Its location in a leading biotech ecosystem enhances innovation and industry partnerships.

Values Reflected in HQ: The headquarters reflects Biogen's commitment to scientific excellence, innovation, sustainability, and creating an environment conducive to groundbreaking neurological research.

Location:

Biogen supports a worldwide network encompassing research and development sites, advanced manufacturing facilities, and commercial operations in numerous countries. This global infrastructure enables the company to discover, develop, and deliver its innovative therapies to patients across North America, Europe, Asia, Latin America, and other regions.

Street Address:

225 Binney Street

City:

Cambridge

State/Province:

Massachusetts

Country:

USA

Biogen's Global Presence

Research Triangle Park, North Carolina, USA

Address: 5000 Davis Dr, Research Triangle Park, NC 27709, USA (Representative address, Biogen has multiple facilities in RTP)

Leverages the Research Triangle Park's rich biotech ecosystem, skilled workforce, and established infrastructure for pharmaceutical manufacturing and research.

Luterbach, Solothurn, Switzerland

Address: Attisholzstrasse 10, 4542 Luterbach, Switzerland

Serves as a strategic European manufacturing hub, ensuring supply chain resilience and access to advanced manufacturing technology and expertise in Europe.

Baar, Zug, Switzerland

Address: Neuhofstrasse 30, 6340 Baar, Switzerland

Acts as a central point for managing Biogen's diverse international markets, benefiting from Switzerland's central European location and established pharmaceutical industry presence.

Buying Intent Signals for Biogen

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Biogen

As of April 2025, Biogen' leadership includes:

Christopher A. Viehbacher - President and Chief Executive Officer
Michael McDonnell - Executive Vice President and Chief Financial Officer
Priya Singhal, M.D., M.P.H. - Executive Vice President, Head of Development, and Interim Head of Research & Early Development
Adam Keeney, Ph.D. - Executive Vice President, Head of Corporate Development
Susan C. Alexander - Executive Vice President, Chief Legal Officer, Secretary, and Interim Chief People Officer
Alisha Alaimo - Executive Vice President, Head of Global Therapeutic Operations
Nicole Murphy - Executive Vice President, Head of Global Manufacturing and Technical Operations

Investors of Biogen

Biogen has been backed by several prominent investors over the years, including:

The Vanguard Group, Inc.
BlackRock, Inc.
State Street Corporation
PRIMECAP Management Company
FMR LLC (Fidelity Management & Research)

Executive New Hires/Exits in the Last 12 Months

Hire3
Exits3

Over the past year, Biogen has experienced notable executive transitions, including key appointments to its leadership team in areas like Development and Corporate Development, alongside a strategic reorganization of its commercial leadership. These changes reflect the company's ongoing evolution under new CEO Christopher A. Viehbacher and its focus on advancing its neuroscience pipeline and commercial strategy. Several departures of senior executives have also occurred during this period of transformation.

Departures

Chirfi Guindo, Chirfi Guindo departed his role leading Biogen's global commercial strategy and operations.
Ginger Gregory, Ph.D., Ginger Gregory stepped down from her position as Chief Human Resources Officer.
Brian McKenzie, Brian McKenzie, who served as SVP and Chief Accounting Officer, left Biogen.

New Appointments:

Adam Keeney, Ph.D., Adam Keeney joined Biogen to lead corporate development, strategy, and M&A activities.
Priya Singhal, M.D., M.P.H., Priya Singhal was appointed to lead Biogen's global development organization and clinical trial operations.
Alisha Alaimo, Alisha Alaimo, previously President of Biogen's U.S. Organization, was promoted to oversee global therapeutic operations.

Technology (Tech Stack) used by Biogen

Discover the tools Biogen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Biogen Email Formats and Examples

Biogen commonly uses the firstname.lastname email format for its employees. Variations might exist, but this is the most frequently observed pattern.

firstname.lastname@biogen.com

Format

jane.doe@biogen.com

Example

90%

Success rate

News and media

Biogen Investor RelationsMay 7, 2024

Biogen Announces Positive Topline Results from Phase 1/2 Study of Investigational ASO BIIB105 in Angelman Syndrome

Biogen reported promising early-stage clinical trial data for BIIB105, an investigational antisense oligonucleotide (ASO) therapy for Angelman syndrome, indicating improvements in multiple areas of clinical development for patients....more

Biogen Investor RelationsApril 24, 2024

Biogen Reports First Quarter 2024 Results

Biogen announced its Q1 2024 financial results, exceeding profit expectations due to cost management and increasing sales of its Alzheimer's drug, Leqembi. The company reaffirmed its full-year financial guidance....more

Biogen Investor RelationsMarch 12, 2024

Biogen to Strengthen Pipeline with Late-Stage Immunology Asset Through Planned Acquisition of Human Immunology Biosciences (HI-Bio™)

Biogen announced its definitive agreement to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in potential milestone payments. The acquisition aims to enhance Biogen's immunology pipeline, notably with felzartamab, a late-stage candidate for rare immune diseases....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Biogen, are just a search away.